Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Cervical Cancer

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 127 articles:
HTML format



Single Articles


    July 2024
  1. GILHAM C, Nedjai B, Scibior-Bentkowska D, Reuter C, et al
    Long-term prediction by DNA methylation of high-grade cervical intraepithelial neoplasia: Results of the ARTISTIC cohort.
    Int J Cancer. 2024;155:81-92.
    PubMed     Abstract available


    May 2024
  2. LOBIN C, Orang'o EO, Were E, Muthoka K, et al
    Cost-effectiveness analysis of alternative screening strategies for the detection of cervical cancer among women in rural areas of Western Kenya.
    Int J Cancer. 2024 May 27. doi: 10.1002/ijc.35036.
    PubMed     Abstract available


  3. HANSEN BT, Nygard M, Castle PE, Burger EA, et al
    Sociodemographic characteristics associated with cervical cancer screening participation by send-to-all and opt-in HPV self-sampling: Who benefits? Results from a randomized controlled trial among long-term non-attending women in Norway.
    Int J Cancer. 2024 May 15. doi: 10.1002/ijc.34989.
    PubMed     Abstract available


    April 2024
  4. DOWNHAM L, Rol ML, Forestier M, Romero P, et al
    Field experience with the 8-HPV-type oncoprotein test for cervical cancer screening among HPV-positive women living with and without HIV in LMICs.
    Int J Cancer. 2024 Apr 11. doi: 10.1002/ijc.34953.
    PubMed     Abstract available


    March 2024
  5. PORTNOY A, Pedersen K, Sy S, Trope A, et al
    Cost-effectiveness of primary human papillomavirus triage approaches among vaccinated women in Norway: A model-based analysis.
    Int J Cancer. 2024;154:1073-1081.
    PubMed     Abstract available


  6. LI N, Yi H, Sun W, Sundquist J, et al
    Revealing genes associated with cervical cancer in distinct immune cells: A comprehensive Mendelian randomization analysis.
    Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34911.
    PubMed     Abstract available


  7. STERPETTI AV, Gabriele R, Iannone I, Sapienza P, et al
    Reduced adherence to cervical cancer screening. The importance of information and education for women with low education and low-income.
    Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34907.
    PubMed    


  8. OLTHOF EMG, Aitken CA, Siebers AG, van Kemenade FJ, et al
    The impact of loss to follow-up in the Dutch organised HPV-based cervical cancer screening programme.
    Int J Cancer. 2024 Mar 4. doi: 10.1002/ijc.34902.
    PubMed     Abstract available


    February 2024
  9. LINDQUIST S, Frederiksen K, Petersen LK, Kjaer SK, et al
    The risk of vaginal, vulvar and anal precancer and cancer according to high-risk HPV status in cervical cytology samples.
    Int J Cancer. 2024 Feb 28. doi: 10.1002/ijc.34896.
    PubMed     Abstract available


  10. WEN TM, Xu XQ, Zhao XL, Pan CH, et al
    Efficacy and immunogenicity of AS04-HPV-16/18 vaccine in females with existing cervical HR-HPV infection at first vaccination: A pooled analysis of four large clinical trials worldwide.
    Int J Cancer. 2024 Feb 17. doi: 10.1002/ijc.34882.
    PubMed     Abstract available


    January 2024
  11. AMBOREE TL, Damgacioglu H, Sonawane K, Adsul P, et al
    Recent trends in cervical cancer incidence, stage at diagnosis, and mortality according to county-level income in the United States, 2000-2019.
    Int J Cancer. 2024 Jan 25. doi: 10.1002/ijc.34860.
    PubMed     Abstract available


  12. LEHTINEN M, Bruni L, Elfstrom M, Gray P, et al
    Scientific approaches toward improving cervical cancer elimination strategies.
    Int J Cancer. 2024 Jan 9. doi: 10.1002/ijc.34839.
    PubMed     Abstract available


  13. EL-ZEIN M, Cheishvili D, Szyf M, Franco EL, et al
    Validation of novel DNA methylation markers in cervical precancer and cancer.
    Int J Cancer. 2024;154:104-113.
    PubMed     Abstract available


    December 2023

  14. Harald zur Hausen 1936-2023.
    Int J Cancer. 2023;153:1937-1939.
    PubMed    


  15. DICK S, Heideman DAM, Mom CH, Meijer CJLM, et al
    Methylation testing for the detection of recurrent cervical intraepithelial neoplasia.
    Int J Cancer. 2023;153:2011-2018.
    PubMed     Abstract available


    November 2023
  16. TULSIDAS S, Fontes F, Monteiro K, Mussa M, et al
    Cervical cancer in Mozambique: Clinical characteristics, treatment and survival of incident cases admitted to the Oncology Service of Maputo Central Hospital in 2016-2018.
    Int J Cancer. 2023 Nov 14. doi: 10.1002/ijc.34779.
    PubMed     Abstract available


  17. BONI SP, Tenet V, Horo A, Heideman DAM, et al
    High-risk human papillomavirus distribution according to human immunodeficiency virus status among women with cervical cancer in Abidjan, Cote d'Ivoire, 2018 to 2020.
    Int J Cancer. 2023 Nov 9. doi: 10.1002/ijc.34774.
    PubMed     Abstract available


    October 2023

  18. Correction to "Randomized multicenter phase II trial of prophylactic irradiation of para-aortic lymph nodes in advanced cervical cancer according to tumor hypoxia: Korean Radiation Oncology Group (KROG 07-01) study".
    Int J Cancer. 2023 Oct 31. doi: 10.1002/ijc.34775.
    PubMed    


  19. COCUZZA CE, Dhillon SK, Martinelli M, Giubbi C, et al
    Clinical performance of the novel full-genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT framework.
    Int J Cancer. 2023 Oct 19. doi: 10.1002/ijc.34754.
    PubMed     Abstract available


    September 2023
  20. INTURRISI F, de Sanjose S, Desai KT, Dagnall C, et al
    A rapid HPV typing assay to support global cervical cancer screening and risk-based management: A cross-sectional study.
    Int J Cancer. 2023 Sep 29. doi: 10.1002/ijc.34698.
    PubMed     Abstract available


  21. MUNGO C, Osongo CO, Ambaka J, Omoto J, et al
    Efficacy of thermal ablation for treatment of biopsy-confirmed high-grade cervical precancer among women living with HIV in Kenya.
    Int J Cancer. 2023 Sep 15. doi: 10.1002/ijc.34737.
    PubMed     Abstract available


  22. WANG J, Edvardsson H, Strander B, Andrae B, et al
    Long-term follow-up of cervical cancer incidence after normal cytological findings.
    Int J Cancer. 2023 Sep 11. doi: 10.1002/ijc.34723.
    PubMed     Abstract available


  23. DHOKOTERA TG, Muchengeti M, Davidovic M, Rohner E, et al
    Gynaecologic and breast cancers in women living with HIV in South Africa: A record linkage study.
    Int J Cancer. 2023 Sep 8. doi: 10.1002/ijc.34712.
    PubMed     Abstract available


  24. FERNANDEZ VILLALOBOS NV, Ruffieux Y, Haas AD, Chinogurei C, et al
    Cervical precancer and cancer incidence among insured women with and without HIV in South Africa.
    Int J Cancer. 2023 Sep 2. doi: 10.1002/ijc.34707.
    PubMed     Abstract available


    August 2023
  25. WHITE C, Reynolds S, Murphy K, Keegan H, et al
    Performance of the HPV E6/E7 mRNA Aptima HPV assay combined with partial genotyping compared with the HPV DNA Cobas 4800 HPV test for use in primary screening: Results from the CERVIVA HPV primary screening study in Ireland.
    Int J Cancer. 2023 Aug 26. doi: 10.1002/ijc.34685.
    PubMed     Abstract available


    July 2023
  26. REBOLJ M, Sargent A, Njor SH, Cuschieri K, et al
    Widening the offer of human papillomavirus self-sampling to all women eligible for cervical screening: Make haste slowly.
    Int J Cancer. 2023;153:8-19.
    PubMed     Abstract available


    June 2023
  27. QI L, Wang M, Jia Y, Wang Y, et al
    Impact of the COVID-19 pandemic on the hospital attendance of patients with primary cervical cancer in Heilongjiang, China.
    Int J Cancer. 2023 Jun 1. doi: 10.1002/ijc.34617.
    PubMed     Abstract available


    May 2023
  28. PESOLA F, Rebolj M, Sasieni P
    Managing an extension of screening intervals: Avoiding boom and bust in health care workloads.
    Int J Cancer. 2023;152:2061-2068.
    PubMed     Abstract available


    April 2023
  29. TISLER A, Nygard M, Kivite-Urtane A, Berza N, et al
    Comment on "The European response to the WHO call to eliminate cervical cancer as a public health problem".
    Int J Cancer. 2023 Apr 19. doi: 10.1002/ijc.34540.
    PubMed    


    March 2023
  30. CUZICK J, Adcock R, Kinney W, Castle PE, et al
    Impact of HPV testing in Opportunistic Cervical Screening: Support for Primary HPV Screening in the United States.
    Int J Cancer. 2023 Mar 22. doi: 10.1002/ijc.34519.
    PubMed     Abstract available


  31. WEVER BMM, van den Helder R, van Splunter AP, van Gent MDJM, et al
    DNA methylation testing for endometrial cancer detection in urine, cervicovaginal self-samples, and cervical scrapes.
    Int J Cancer. 2023 Mar 13. doi: 10.1002/ijc.34504.
    PubMed     Abstract available


  32. DONG L, Nygard M, Stoer NC, Klungsoyr O, et al
    Real-World Effectiveness of Hpv Vaccination Against Cervical Neoplasia Among Birth Cohorts Ineligible for Routine Vaccination.
    Int J Cancer. 2023 Mar 3. doi: 10.1002/ijc.34489.
    PubMed     Abstract available


    February 2023
  33. HERZOG C, Vavourakis CD, Barrett JE, Karbon G, et al
    HPV-induced host epigenetic reprogramming is lost upon progression to high-grade cervical intraepithelial neoplasia.
    Int J Cancer. 2023 Feb 21. doi: 10.1002/ijc.34477.
    PubMed     Abstract available


    December 2022
  34. BARRETT JE, Jones A, Evans I, Herzog C, et al
    The WID-EC test for the detection and risk prediction of endometrial cancer.
    Int J Cancer. 2022 Dec 19. doi: 10.1002/ijc.34406.
    PubMed     Abstract available


  35. SAKAKIBARA A, Nakayama T, Uchida H, Odagiri Y, et al
    Trends and future projections of cervical cancer-related outcomes in Japan: What happens if the HPV vaccine program is not implemented?
    Int J Cancer. 2022 Dec 5. doi: 10.1002/ijc.34391.
    PubMed     Abstract available


  36. ROBERTS JM, Machalek DA, Butler BC, Crescini J, et al
    Older women testing positive for HPV 16/18 on cervical screening and risk of high-grade cervical abnormality.
    Int J Cancer. 2022 Dec 5. doi: 10.1002/ijc.34393.
    PubMed     Abstract available


    November 2022
  37. BAENA A, Mesher D, Salgado Y, Martinez S, et al
    Performance of visual inspection of the cervix with acetic acid (VIA) for triage of HPV screen-positive women: results from the ESTAMPA study.
    Int J Cancer. 2022 Nov 30. doi: 10.1002/ijc.34384.
    PubMed     Abstract available


  38. GOTTSCHLICH A, Payne BA, Trawin J, Albert A, et al
    Experiences with thermal ablation for cervical pre-cancer treatment after self-collection HPV-based screening in the ASPIRE Mayuge randomized trial.
    Int J Cancer. 2022 Nov 21. doi: 10.1002/ijc.34369.
    PubMed     Abstract available


    October 2022
  39. SIVARS L, Palsdottir K, Crona Guterstam Y, Falconer H, et al
    The current status of cell-free human papillomavirus DNA as a biomarker in cervical cancer and other HPV-associated tumors: A review.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34333.
    PubMed     Abstract available


  40. RING LL, Munk C, Galanakis M, Tota JE, et al
    Incidence of cervical precancerous lesions and cervical cancer in Denmark from 2000 to 2019 - population impact of multi-cohort vaccination against human papillomavirus infection.
    Int J Cancer. 2022 Oct 17. doi: 10.1002/ijc.34328.
    PubMed     Abstract available


  41. YAO J, Takenaga K, Koshikawa N, Kida Y, et al
    Anticancer effect of a pyrrole-imidazole polyamide-triphenylphosphonium conjugate selectively targeting a common mitochondrial DNA cancer risk variant in cervical cancer cells.
    Int J Cancer. 2022 Oct 10. doi: 10.1002/ijc.34319.
    PubMed     Abstract available


  42. SAUVAGET C, Bazikamwe S, Lucas E, Ndayikengurukiye A, et al
    Evaluation of effectiveness, acceptability and safety of thermal ablation in the treatment of cervical neoplasia in Burundi.
    Int J Cancer. 2022;151:1120-1126.
    PubMed     Abstract available


    September 2022
  43. ADEBAMOWO SN, Befano B, Cheung LC, Rodriguez AC, et al
    Different human papillomavirus types share early natural history transitions in immunocompetent women.
    Int J Cancer. 2022;151:920-929.
    PubMed     Abstract available


  44. KAHESA C, Thomsen LT, Linde DS, Mchome B, et al
    Comparison of human papillomavirus (HPV)-based cervical cancer screening strategies in Tanzania among women with and without HIV.
    Int J Cancer. 2022 Sep 12. doi: 10.1002/ijc.34283.
    PubMed     Abstract available


  45. LEHTINEN M, Pimenoff VN, Nedjai B, Louvanto K, et al
    Assessing the risk of cervical neoplasia in the post-HPV vaccination era.
    Int J Cancer. 2022 Sep 12. doi: 10.1002/ijc.34286.
    PubMed     Abstract available


  46. SCHREIBERHUBER L, Herzog C, Vavourakis CD, Redl E, et al
    The WID(TM) -qEC test - performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers.
    Int J Cancer. 2022 Sep 2. doi: 10.1002/ijc.34275.
    PubMed     Abstract available


    August 2022
  47. FRENSEMEIER K, Holzer A, Hoppe-Seyler K, Hoppe-Seyler F, et al
    Dickkopf-1 expression is repressed by oncogenic human papillomaviruses (HPVs) and regulates the Cisplatin sensitivity of HPV-positive cancer cells in a JNK-dependent manner.
    Int J Cancer. 2022 Aug 19. doi: 10.1002/ijc.34250.
    PubMed     Abstract available


  48. NORMAN I, Yilmaz E, Hjerpe A, Hortlund M, et al
    Atypical glandular cells and development of cervical cancer: Population-based cohort study.
    Int J Cancer. 2022 Aug 13. doi: 10.1002/ijc.34242.
    PubMed     Abstract available


  49. SENGAYI-MUCHENGETI M, Singh E, Chen WC, Bradshaw D, et al
    Thirteen cancers associated with HIV infection in a Black South African cancer patient population (1995-2016).
    Int J Cancer. 2022 Aug 4. doi: 10.1002/ijc.34236.
    PubMed     Abstract available


    July 2022
  50. GARGANO JW, McClung N, Lewis RM, Park IU, et al
    HPV type-specific trends in cervical precancers in the United States, 2008-2016.
    Int J Cancer. 2022 Jul 29. doi: 10.1002/ijc.34231.
    PubMed     Abstract available


  51. JOSHI S, Muwonge R, Kulkarni V, Mandolkar M, et al
    Can we increase the cervical cancer screening interval with an HPV test for women living with HIV? Results of a cohort study from Maharashtra, India.
    Int J Cancer. 2022 Jul 19. doi: 10.1002/ijc.34221.
    PubMed     Abstract available


    June 2022
  52. YOON M, Lee HK, Park EY, Kim JH, et al
    Randomized multicenter phase II trial of prophylactic irradiation of para-aortic lymph nodes in advanced cervical cancer according to tumor hypoxia: Korean Radiation Oncology Group (KROG 07-01) study.
    Int J Cancer. 2022 Jun 25. doi: 10.1002/ijc.34190.
    PubMed     Abstract available


  53. AUVINEN E, Nieminen P, Pellinen J, Dillner J, et al
    HPV self-sampling with mRNA testing benefits routine screening.
    Int J Cancer. 2022 Jun 18. doi: 10.1002/ijc.34170.
    PubMed     Abstract available


  54. DESAI KT, Adepiti CA, Schiffman M, Egemen D, et al
    Redesign of a rapid, low-cost HPV typing assay to support risk-based cervical screening and management.
    Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34151.
    PubMed     Abstract available


  55. HAMPL M, Hesselink AT, Meijer CJLM, Denecke A, et al
    Evaluation of FAM19A4/miR124-2 methylation performance in the management of CIN3 diagnosed pregnant women.
    Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34153.
    PubMed     Abstract available


    May 2022
  56. GIORGI ROSSI P, Ronco G, Mancuso P, Carozzi F, et al
    Performance of HPV E6/E7 mRNA Assay as Primary Screening Test. Results from the NTCC2 Trial.
    Int J Cancer. 2022 May 17. doi: 10.1002/ijc.34120.
    PubMed     Abstract available


  57. BURGER EA, Laprise JF, Sy S, Regan MC, et al
    Now or later: Health impacts of delaying single-dose HPV vaccine implementation in a high-burden setting.
    Int J Cancer. 2022 May 5. doi: 10.1002/ijc.34054.
    PubMed     Abstract available


  58. HURTADO-SALGADO E, Cardenas-Cardenas L, Salmeron J, Luna-Gordillo R, et al
    Comparative performance of the human papillomavirus test and cytology for primary screening for high-grade cervical intraepithelial neoplasia at the population level.
    Int J Cancer. 2022;150:1422-1430.
    PubMed     Abstract available


    April 2022
  59. ADCOCK R, Nedjai B, Lorincz A, Scibior-Bentkowska D, et al
    DNA methylation testing with S5 for triage of high-risk HPV positive women.
    Int J Cancer. 2022 Apr 27. doi: 10.1002/ijc.34050.
    PubMed     Abstract available


  60. GOTTSCHLICH A, Gondara L, Smith LW, Cook D, et al
    HPV-based screening at extended intervals missed fewer cervical precancers than cytology in the HPV FOr CervicAL Cancer (HPV FOCAL) trial.
    Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34039.
    PubMed     Abstract available


  61. ZHANG L, Zhao X, Hu S, Chen S, et al
    Triage performance and predictive value of the human gene methylation panel among women positive on self-collected HPV test: results from a prospective cohort study.
    Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34041.
    PubMed     Abstract available


  62. STANCZUK GA, Currie H, Forson W, Baxter G, et al
    Self-sampling as the principal modality for population based cervical screening: Five-year follow-up of the PaVDaG study.
    Int J Cancer. 2022;150:1350-1356.
    PubMed     Abstract available


  63. SAHASRABUDDHE VV, Castle PE, Schiffman M, Wentzensen N, et al
    Reply to: Comments on 'Meta-analysis of agreement/concordance statistics in studies comparing self- versus clinician-collected samples for HPV testing in cervical cancer screening'.
    Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34013.
    PubMed    


  64. BRENTNALL AR, Rebolj M
    Comments on: "Meta-analysis of agreement/concordance statistics in studies comparing self-versus clinician-collected samples for HPV testing in cervical cancer screening".
    Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34014.
    PubMed    


    February 2022
  65. ARBYN M, Castle PE, Schiffman M, Wentzensen N, et al
    Meta-analysis of agreement/concordance statistics in studies comparing self- versus clinician-collected samples for HPV testing in cervical cancer screening.
    Int J Cancer. 2022 Feb 18. doi: 10.1002/ijc.33967.
    PubMed     Abstract available


    January 2022
  66. VAN DER WATT PJ, Okpara MO, Wishart A, Parker MI, et al
    Nuclear transport proteins are secreted by cancer cells and identified as potential novel cancer biomarkers.
    Int J Cancer. 2022;150:347-361.
    PubMed     Abstract available


    December 2021
  67. HORTLUND M, Muhr LSA, Lagheden C, Hjerpe A, et al
    Audit of laboratory sensitivity of human papillomavirus and cytology testing in a cervical screening program.
    Int J Cancer. 2021;149:2083-2090.
    PubMed     Abstract available


  68. REBOLJ M, Mathews CS, Pesola F, Castanon A, et al
    Acceleration of Cervical Cancer Diagnosis with Human Papillomavirus Testing Below Age 30: Observational Study.
    Int J Cancer. 2021 Dec 12. doi: 10.1002/ijc.33900.
    PubMed     Abstract available


    November 2021
  69. DESAI KT, Befano B, Xue Z, Kelly H, et al
    The development of "Automated Visual Evaluation" for cervical cancer screening: The promise and challenges in adapting deep-learning for clinical testing.
    Int J Cancer. 2021 Nov 20. doi: 10.1002/ijc.33879.
    PubMed     Abstract available


  70. SPENCER JC, Campos NG, Burger EA, Sy S, et al
    Potential Effectiveness of a Therapeutic HPV Intervention Campaign in Uganda.
    Int J Cancer. 2021 Nov 6. doi: 10.1002/ijc.33867.
    PubMed     Abstract available


    October 2021
  71. GUSTINUCCI D, Benevolo M, Cesarini E, Mancuso P, et al
    Accuracy of Different Triage Strategies for HPV Positivity in an Italian Screening Population.
    Int J Cancer. 2021 Oct 27. doi: 10.1002/ijc.33858.
    PubMed     Abstract available


  72. HARPER DM, Rozek LS
    Cervical cancer prevention becomes more efficient.
    Int J Cancer. 2021 Oct 19. doi: 10.1002/ijc.33851.
    PubMed    


  73. PEDERSEN K, Portnoy A, Sy S, Hansen BT, et al
    Switching clinic-based cervical cancer screening programs to HPV self-sampling: A cost-effectiveness analysis of vaccinated and unvaccinated Norwegian women.
    Int J Cancer. 2021 Oct 18. doi: 10.1002/ijc.33850.
    PubMed     Abstract available


  74. IBRAHIM KHALIL A, Mpunga T, Wei F, Baussano I, et al
    Age-specific burden of cervical cancer associated with HIV: a global analysis with a focus on sub-Saharan Africa.
    Int J Cancer. 2021 Oct 9. doi: 10.1002/ijc.33841.
    PubMed     Abstract available


    September 2021
  75. BANILA C, Lorincz AT, Scibior-Bentkowska D, Clifford GM, et al
    Clinical performance of methylation as a biomarker for cervical carcinoma-in-situ and cancer diagnosis: a worldwide study.
    Int J Cancer. 2021 Sep 25. doi: 10.1002/ijc.33815.
    PubMed     Abstract available


  76. VERHOEF L, Bleeker MCG, Polman N, Steenbergen RDM, et al
    Performance of DNA methylation analysis of ASCL1, LHX8, ST6GALNAC5, GHSR, ZIC1 and SST for the triage of HPV-positive women: results from a Dutch primary HPV-based screening cohort.
    Int J Cancer. 2021 Sep 24. doi: 10.1002/ijc.33820.
    PubMed     Abstract available


  77. WRIGHT TC JR, Stoler MH, Ranger-Moore J, Fang Q, et al
    Clinical Validation of p16/Ki-67 Dual-Stained Cytology Triage of HPV-Positive Women - Results from the IMPACT Trial.
    Int J Cancer. 2021 Sep 18. doi: 10.1002/ijc.33812.
    PubMed     Abstract available


    August 2021
  78. SALTA S, Maia-Moco L, Estevao-Pereira H, Sequeira JP, et al
    Performance of DNA methylation-based biomarkers in the Cervical Cancer Screening Program of Northern Portugal: a feasibility study.
    Int J Cancer. 2021 Aug 30. doi: 10.1002/ijc.33778.
    PubMed     Abstract available


  79. KEANE A, Ng CW, Simms KT, Nguyen D, et al
    The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost-effectiveness of HPV screening with self-collection and digital registry support.
    Int J Cancer. 2021 Aug 7. doi: 10.1002/ijc.33759.
    PubMed     Abstract available


    June 2021
  80. VAN SCHALKWYK C, Moodley J, Welte A, Johnson LF, et al
    Modelling the impact of prevention strategies on cervical cancer incidence in South Africa.
    Int J Cancer. 2021 Jun 24. doi: 10.1002/ijc.33716.
    PubMed     Abstract available


  81. BUDUKH A, Dikshit R, Chaturvedi P
    Outcome of the randomized control screening trials on Oral, Cervix and Breast Cancer from India and way forward in COVID-19 pandemic situation.
    Int J Cancer. 2021 Jun 21. doi: 10.1002/ijc.33712.
    PubMed    


  82. JAYARAJ R, Shaw P, Kumarasamy C, Shetty SS, et al
    Comments on "Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis".
    Int J Cancer. 2021;148:2857-2858.
    PubMed    


  83. MALAGON T, Volesky KD, Franco EL
    Reply to: Comments on cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis.
    Int J Cancer. 2021;148:2859-2860.
    PubMed    


    May 2021
  84. DEREJE N, Addissie A, Worku A, Gebremariam A, et al
    Association between waiting time for radiotherapy initiation and disease progression among women with cervical cancer in Addis Ababa, Ethiopia.
    Int J Cancer. 2021 May 17. doi: 10.1002/ijc.33689.
    PubMed     Abstract available


  85. KITAZAWA S, Takaoka Y, Ueda Y, Kitazawa R, et al
    Identification of Calmodulin-Like Protein 5 (CALML5) as tumor-suppressor gene silenced during early stage of carcinogenesis in squamous cell carcinoma of uterine cervix.
    Int J Cancer. 2021 May 17. doi: 10.1002/ijc.33687.
    PubMed     Abstract available


    April 2021
  86. RAMACHANDRAN D, Wang Y, Schurmann P, Hulse F, et al
    Association of genomic variants at PAX8 and PBX2 with cervical cancer risk.
    Int J Cancer. 2021 Apr 27. doi: 10.1002/ijc.33614.
    PubMed     Abstract available


  87. GREEN LI, Mathews CS, Waller J, Kitchener H, et al
    Attendance at early recall and colposcopy in routine cervical screening with human papillomavirus testing.
    Int J Cancer. 2021;148:1850-1857.
    PubMed     Abstract available


  88. HOPPE-SEYLER K, Herrmann AL, Daschle A, Kuhn BJ, et al
    Effects of Metformin on the virus/host cell crosstalk in HPV-positive cancer cells.
    Int J Cancer. 2021 Apr 12. doi: 10.1002/ijc.33594.
    PubMed    


  89. BORGFELDT C, Soderlund-Strand A, Darlin Flygh L, Forslund O, et al
    HPV73 in cervical cancer and distribution of HPV73 variants in cervical dysplasia.
    Int J Cancer. 2021 Apr 9. doi: 10.1002/ijc.33590.
    PubMed     Abstract available


  90. IVERSEN L, Fielding S, Lidegaard O, Hannaford PC, et al
    Contemporary hormonal contraception and cervical cancer in women of reproductive age.
    Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33585.
    PubMed     Abstract available


  91. PARRA SG, Lopez-Orellana LM, Molina Duque AR, Carns JL, et al
    Reply to: Comments on Cervical cancer prevention in El Salvador: A prospective evaluation of screening and triage strategies incorporating high-resolution microendoscopy to detect cervical precancer.
    Int J Cancer. 2021 Apr 4. doi: 10.1002/ijc.33586.
    PubMed    


  92. PRETORIUS RG, Belinson JL
    COMMENTS ON: CERVICAL CANCER PREVENTION IN EL SALVADOR: A PROSPECTIVE EVALUATION OF SCREENING AND TRIAGE STRATEGIES INCORPORATING HIGH-RESOLUTION MICROENDOSCOPY TO DETECT CERVICAL PRECANCER.
    Int J Cancer. 2021 Apr 4. doi: 10.1002/ijc.33587.
    PubMed    


  93. LI N, Hu Y, Zhang X, Liu Y, et al
    DNA methylation markers as triage test for the early identification of cervical lesions in a Chinese population.
    Int J Cancer. 2021;148:1768-1777.
    PubMed     Abstract available


    March 2021
  94. VINK FJ, Dick S, Heideman DAM, De Strooper LMA, et al
    Classification of high-grade CIN by p16(ink4a) , Ki-67, HPV E4 and FAM19A4/miR124-2 methylation status demonstrates considerable heterogeneity with potential consequences for management.
    Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33566.
    PubMed     Abstract available


  95. ZHAO XL, Liu ZH, Zhao S, Hu SY, et al
    Efficacy of point-of-care thermal ablation among high-risk human papillomavirus positive women in China.
    Int J Cancer. 2021;148:1419-1427.
    PubMed     Abstract available


  96. CHINULA L, Topazian HM, Mapanje C, Varela A, et al
    Uptake and safety of community-based 'screen-and-treat' with thermal ablation preventive therapy for cervical cancer prevention in rural Lilongwe, Malawi.
    Int J Cancer. 2021 Mar 9. doi: 10.1002/ijc.33549.
    PubMed     Abstract available


    February 2021
  97. HALL MT, Smith MA, Simms KT, Barnabas R, et al
    Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV control.
    Int J Cancer. 2021 Feb 26. doi: 10.1002/ijc.33533.
    PubMed     Abstract available


  98. HORTLUND M, van Mol T, Van de Pol F, Bogers JP, et al
    Human Papillomavirus Load and Genotype Analysis Improves the Prediction of Invasive Cervical Cancer.
    Int J Cancer. 2021 Feb 14. doi: 10.1002/ijc.33519.
    PubMed     Abstract available


  99. DONKEN R, van Niekerk D, Hamm J, Spinelli JJ, et al
    Declining Rates of Cervical Intraepithelial Neoplasia in British Columbia, Canada: An Ecological Analysis On The Effects of The School-Based HPV Vaccination Program.
    Int J Cancer. 2021 Feb 14. doi: 10.1002/ijc.33513.
    PubMed    


  100. HUANG HJ, Tung HJ, Yang LY, Chao A, et al
    Role of human papillomavirus status after conization for high-grade cervical intraepithelial neoplasia.
    Int J Cancer. 2021;148:665-672.
    PubMed     Abstract available


    January 2021
  101. EL-ZEIN M, Gotlieb W, Gilbert L, Hemmings R, et al
    Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
    Int J Cancer. 2021;148:492-501.
    PubMed     Abstract available


  102. INTURRISI F, Lissenberg-Witte BI, Veldhuijzen NJ, Bogaards JA, et al
    Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer.
    Int J Cancer. 2021;148:320-328.
    PubMed     Abstract available


    December 2020
  103. PARRA SG, Lopez-Orellana LM, Molina Duque AR, Carns JL, et al
    Cervical cancer prevention in El Salvador: A prospective evaluation of screening and triage strategies incorporating high-resolution microendoscopy to detect cervical precancer.
    Int J Cancer. 2020 Dec 24. doi: 10.1002/ijc.33454.
    PubMed     Abstract available


    November 2020
  104. LU Z, Zhu M, Marley JL, Bi K, et al
    The combined action of Mo-MDSCs and MAIT cells promotes the progression of cervical cancer.
    Int J Cancer. 2020 Nov 27. doi: 10.1002/ijc.33411.
    PubMed     Abstract available


  105. MALAGON T, Volesky KD, Bouten S, Laprise C, et al
    Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis.
    Int J Cancer. 2020;147:2695-2707.
    PubMed     Abstract available


  106. PINHEIRO M, Gage JC, Clifford GM, Demarco M, et al
    Association of HPV35 with cervical carcinogenesis among women of African ancestry: Evidence of viral-host interaction with implications for disease intervention.
    Int J Cancer. 2020;147:2677-2686.
    PubMed     Abstract available


  107. BIZZARRI N, Anchora LP, Cattani P, De Vincenzo R, et al
    Peritoneal Hpv-Dna Test In Cervical Cancer (Pioneer Study): A Proof Of Concept.
    Int J Cancer. 2020 Nov 5. doi: 10.1002/ijc.33380.
    PubMed     Abstract available


  108. XUE Z, Novetsky AP, Einstein MH, Marcus JZ, et al
    A demonstration of automated visual evaluation of cervical images taken with a smartphone camera.
    Int J Cancer. 2020;147:2416-2423.
    PubMed     Abstract available


    October 2020
  109. TIAN X, Ge D, Zhang F, Zhang B, et al
    Dynamic analysis of circulating tumor DNA to predict prognosis and monitor therapeutic response in metastatic relapsed cervical cancer.
    Int J Cancer. 2020 Oct 28. doi: 10.1002/ijc.33362.
    PubMed     Abstract available


  110. REZHAKE R, Chen F, Hu SY, Zhao XL, et al
    Triage options to manage high-risk human papillomavirus-positive women: A population-based cross-sectional study from rural China.
    Int J Cancer. 2020;147:2053-2064.
    PubMed     Abstract available


  111. RAMIREZ AT, Sanchez GI, Nedjai B, Agudelo MC, et al
    Effective methylation triage of HPV positive women with abnormal cytology in a middle-income country.
    Int J Cancer. 2020 Oct 2. doi: 10.1002/ijc.33314.
    PubMed     Abstract available


  112. CUZICK J, Adcock R, Carozzi F, Gillio-Tos A, et al
    Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening.
    Int J Cancer. 2020;147:1864-1873.
    PubMed     Abstract available


    September 2020
  113. BONDE J, Floore A, Ejegod D, Vink FJ, et al
    Methylation markers FAM19A4 and miR124-2 as triage strategy for primary HPV screen positive women; A large European multi-center study.
    Int J Cancer. 2020 Sep 30. doi: 10.1002/ijc.33320.
    PubMed     Abstract available


  114. EL-ZEIN M, Cheishvili D, Gotlieb W, Gilbert L, et al
    Genome-wide DNA methylation profiling identifies two novel genes in cervical neoplasia.
    Int J Cancer. 2020;147:1264-1274.
    PubMed     Abstract available


    August 2020
  115. LOOPIK DL, Ebisch RM, IntHout J, Melchers WJ, et al
    The relative risk of noncervical high-risk human papillomavirus-related (pre)malignancies after recurrent cervical intraepithelial neoplasia grade 3: A population-based study.
    Int J Cancer. 2020;147:897-900.
    PubMed     Abstract available


  116. WALPOLE E, Dunn N, Youl P, Harden H, et al
    Nonbreast cancer incidence, treatment received and outcomes: Are there differences in breast screening attendees versus nonattendees?
    Int J Cancer. 2020;147:856-865.
    PubMed     Abstract available


    July 2020
  117. BURGER EA, Portnoy A, Campos NG, Sy S, et al
    Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries.
    Int J Cancer. 2020 Jul 24. doi: 10.1002/ijc.33233.
    PubMed     Abstract available


  118. LOUVANTO K, Eriksson T, Gray P, Apter D, et al
    Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women.
    Int J Cancer. 2020;147:440-447.
    PubMed     Abstract available


  119. PONTI A, Basu P, Ritchie D, Anttila A, et al
    Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening.
    Int J Cancer. 2020;147:9-13.
    PubMed     Abstract available


    June 2020
  120. FARNSWORTH A, Roberts JM, Garland SM, Crescini J, et al
    Detection of high-grade cervical disease among women referred directly to colposcopy following a positive HPV screening test varies with age and cytology findings.
    Int J Cancer. 2020 Jun 2. doi: 10.1002/ijc.33128.
    PubMed     Abstract available


    May 2020
  121. JENKINS D, Molijn A, Kazem S, Pirog EC, et al
    Molecular and pathological basis of HPV-negative cervical adenocarcinoma seen in a global study.
    Int J Cancer. 2020 May 31. doi: 10.1002/ijc.33124.
    PubMed     Abstract available


    January 2020
  122. TRICKEY A, May MT, Gill MJ, Grabar S, et al
    Cause-specific mortality after diagnosis of cancer among HIV-positive patients: a collaborative analysis of cohort studies.
    Int J Cancer. 2020 Jan 31. doi: 10.1002/ijc.32895.
    PubMed     Abstract available


  123. ZHAO XL, Xu XQ, Duan XZ, Rezhake R, et al
    Comparative performance evaluation of different HPV tests and triaging strategies using self-samples and feasibility assessment of thermal ablation in 'colposcopy and treat' approach: a population-based study in rural China.
    Int J Cancer. 2020 Jan 22. doi: 10.1002/ijc.32881.
    PubMed     Abstract available


  124. CHAN K, Liu SS, Wei N, Ngu SF, et al
    Primary HPV testing with cytology versus cytology alone in cervical screening - a prospective randomized controlled trial (RCT) with two rounds of screening in a Chinese population.
    Int J Cancer. 2020 Jan 10. doi: 10.1002/ijc.32861.
    PubMed     Abstract available


    October 2019
  125. SAND FL, Kjaer SK, Frederiksen K, Dehlendorff C, et al
    Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status.
    Int J Cancer. 2019 Oct 24. doi: 10.1002/ijc.32752.
    PubMed     Abstract available


  126. ZORZI M, Del Mistro A, Giorgi Rossi P, Laurino L, et al
    Risk of CIN2 or more severe lesions after negative HPV-mRNA E6/E7 overexpression assay and after negative HPV-DNA test: concurrent cohorts with a 5-year follow up.
    Int J Cancer. 2019 Oct 3. doi: 10.1002/ijc.32695.
    PubMed     Abstract available


  127. CASTLE PE, Burk RD, Massad LS, Eltoum IE, et al
    Epidemiological Evidence that Common HPV Types May Be Common Because of Their Ability to Evade Immune Surveillance: Results from the Women's Interagency HIV Study.
    Int J Cancer. 2019 Oct 2. doi: 10.1002/ijc.32693.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Cervical Cancer is free of charge.